Lali Medina-Kauwe, Ph.D.
Developer of the Nanoparticle Technology and co-Founder of Eos Biosciences. Professor, Department of Biomedical Sciences, Cedars-Sinai Medical Center (Los Angeles, CA) and Geffen School of Medicine, University of California Los Angeles (Los Angeles, CA). Dr. Medina-Kauwe is a leader in the field of Nanomedicine and nanoparticle-based drug delivery.
Peter Linsley, Ph.D.
Expertise in RNAi therapeutics, Oncology and Immunology. Research Associate Member, Benaroya Research Institute (Seattle, WA). Previously: Director, BMS (Seattle, WA); Vice President, Rosetta InPharmatics (Kirkland, WA); Executive Director, Merck (Seattle, WA); CSO, Regulus (San Diego, CA). Dr. Linsley has developed many drugs that have progressed to market registration or late stage clinical development in multiple disease areas.
Michael Kahn, Ph.D.
Expertise in Oncology, Peptidomimetics, Molecular & Cell Biology. Professor and Chairman of Molecular Medicine and co-Leader for the Developmental Therapeutics Program, City of Hope (Duarte, CA). Previously: Professor, Center for Stem Cell and Regenerative Medicine, USC (Los Angeles, CA). Dr. Kahn is a leader in the field of stem cell biology and specifically cancer stem cell growth and regulation.